Cargando…

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line the...

Descripción completa

Detalles Bibliográficos
Autores principales: Koie, Takuya, Ohyama, Chikara, Yoneyama, Takahiro, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki, Mori, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/
https://www.ncbi.nlm.nih.gov/pubmed/25887125
http://dx.doi.org/10.1186/s12894-015-0027-4
_version_ 1782369328516038656
author Koie, Takuya
Ohyama, Chikara
Yoneyama, Takahiro
Yamamoto, Hayato
Imai, Atsushi
Hatakeyama, Shingo
Hashimoto, Yasuhiro
Yoneyama, Tohru
Tobisawa, Yuki
Mori, Kazuyuki
author_facet Koie, Takuya
Ohyama, Chikara
Yoneyama, Takahiro
Yamamoto, Hayato
Imai, Atsushi
Hatakeyama, Shingo
Hashimoto, Yasuhiro
Yoneyama, Tohru
Tobisawa, Yuki
Mori, Kazuyuki
author_sort Koie, Takuya
collection PubMed
description BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced RCC or mRCC. METHODS: In this retrospective study, we focused on eighteen patients who underwent first-line therapy with axitinib between May 2012 and May 2014 at Hirosaki University. Axitinib was orally administered at a dose of 10 mg daily. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included overall response rate (ORR) and adverse events (AEs). RESULTS: All patients had histologically proven clear cell RCC. The median duration of the administration of axitinib was 10.8 months. According to the response evaluation criteria for solid tumors, five patients (27.8%) achieved a partial response and nine (50%) had stable disease. The 1-year PFS rate was 84.4%, and the median PFS was 20.4 months (95% confidence interval, 17.5 – 21.7). No serious AEs were reported during the study, and there were no toxicity-related deaths. CONCLUSIONS: In the current study, axitinib showed acceptable oncological outcomes and favorable safety profile as first-line therapy for locally advanced RCC or mRCC in treatment-naïve Japanese patients. Thus, first-line therapy with axitinib may provide a feasible option for treatment of advanced RCC or mRCC patients.
format Online
Article
Text
id pubmed-4417199
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44171992015-05-03 Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan Koie, Takuya Ohyama, Chikara Yoneyama, Takahiro Yamamoto, Hayato Imai, Atsushi Hatakeyama, Shingo Hashimoto, Yasuhiro Yoneyama, Tohru Tobisawa, Yuki Mori, Kazuyuki BMC Urol Research Article BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced RCC or mRCC. METHODS: In this retrospective study, we focused on eighteen patients who underwent first-line therapy with axitinib between May 2012 and May 2014 at Hirosaki University. Axitinib was orally administered at a dose of 10 mg daily. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included overall response rate (ORR) and adverse events (AEs). RESULTS: All patients had histologically proven clear cell RCC. The median duration of the administration of axitinib was 10.8 months. According to the response evaluation criteria for solid tumors, five patients (27.8%) achieved a partial response and nine (50%) had stable disease. The 1-year PFS rate was 84.4%, and the median PFS was 20.4 months (95% confidence interval, 17.5 – 21.7). No serious AEs were reported during the study, and there were no toxicity-related deaths. CONCLUSIONS: In the current study, axitinib showed acceptable oncological outcomes and favorable safety profile as first-line therapy for locally advanced RCC or mRCC in treatment-naïve Japanese patients. Thus, first-line therapy with axitinib may provide a feasible option for treatment of advanced RCC or mRCC patients. BioMed Central 2015-04-16 /pmc/articles/PMC4417199/ /pubmed/25887125 http://dx.doi.org/10.1186/s12894-015-0027-4 Text en © Koie et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Koie, Takuya
Ohyama, Chikara
Yoneyama, Takahiro
Yamamoto, Hayato
Imai, Atsushi
Hatakeyama, Shingo
Hashimoto, Yasuhiro
Yoneyama, Tohru
Tobisawa, Yuki
Mori, Kazuyuki
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title_full Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title_fullStr Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title_full_unstemmed Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title_short Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
title_sort feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/
https://www.ncbi.nlm.nih.gov/pubmed/25887125
http://dx.doi.org/10.1186/s12894-015-0027-4
work_keys_str_mv AT koietakuya feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT ohyamachikara feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT yoneyamatakahiro feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT yamamotohayato feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT imaiatsushi feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT hatakeyamashingo feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT hashimotoyasuhiro feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT yoneyamatohru feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT tobisawayuki feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan
AT morikazuyuki feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan